Literature DB >> 21559814

CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.

Hideki Muramatsu1, Yoshiyuki Takahashi1, Yoshie Shimoyama2, Sayoko Doisaki1, Nobuhiro Nishio1, Yoshinori Ito1, Asahito Hama1, Akira Shimada1, Hiroshi Yagasaki1, Masafumi Ito3, Seiji Kojima4.   

Abstract

Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21559814     DOI： 10.1007/s12185-011-0870-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  8 in total

1.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Authors:  Joost W J van Esser; Hubert G M Niesters; Bronno van der Holt; Ellen Meijer; Albert D M E Osterhaus; Jan Willem Gratama; Leo F Verdonck; Bob Löwenberg; Jan J Cornelissen
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

2.  Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

Authors:  A Faye; P Quartier; Y Reguerre; P Lutz; A S Carret; A Dehée; P Rohrlich; M Peuchmaur; A Matthieu-Boué; A Fischer; E Vilmer
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

3.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.

Authors:  I Kuehnle; M H Huls; Z Liu; M Semmelmann; R A Krance; M K Brenner; C M Rooney; H E Heslop
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

4.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

Authors:  E B Papadopoulos; M Ladanyi; D Emanuel; S Mackinnon; F Boulad; M H Carabasi; H Castro-Malaspina; B H Childs; A P Gillio; T N Small
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

Review 5.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

6.  Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.

Authors:  P Comoli; S Basso; M Zecca; D Pagliara; F Baldanti; M E Bernardo; W Barberi; A Moretta; M Labirio; M Paulli; M Furione; R Maccario; F Locatelli
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

7.  Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Authors:  Junji Hiraga; Akihiro Tomita; Takumi Sugimoto; Kazuyuki Shimada; Masafumi Ito; Shigeo Nakamura; Hitoshi Kiyoi; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Blood       Date:  2009-02-26       Impact factor: 22.113

Review 8.  Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Authors:  J Styczynski; H Einsele; L Gil; P Ljungman
Journal:  Transpl Infect Dis       Date:  2009-06-23       Impact factor: 2.228
  8 in total
  5 in total

Review 1.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

Authors:  L Rasche; M Kapp; H Einsele; S Mielke
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

Review 2.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Authors:  Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

3.  Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities.

Authors:  Junyun Lai; Wei Jian Tan; Chien Tei Too; Joanna Ai Ling Choo; Lan Hiong Wong; Fatimah Bte Mustafa; Nalini Srinivasan; Angeline Pei Chiew Lim; Youjia Zhong; Nicholas R J Gascoigne; Brendon J Hanson; Soh Ha Chan; Jianzhu Chen; Paul A MacAry
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

4.  [How I diagnose and treat post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation].

Authors:  L P Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

5.  Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.

Authors:  Takahiro Watanabe; Yoshitaka Sato; H M Abdullah Al Masud; Masahiro Takayama; Hiroki Matsuda; Yuya Hara; Yusuke Yanagi; Masahiro Yoshida; Fumi Goshima; Takayuki Murata; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2019-12-11       Impact factor: 6.716
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.